Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRRXNASDAQ:LGVNNASDAQ:MRKRNASDAQ:TZAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$0.64+6.7%$0.64$0.48▼$1.84$19.87M0.5985,499 shs107,743 shsLGVNLongeveron$1.32-2.9%$1.41$1.14▼$6.40$19.71M0.222.66 million shs113,289 shsMRKRMarker Therapeutics$1.69-9.6%$1.24$0.95▼$5.99$21.16M1.4478,108 shs172,043 shsTZACTenzing Acquisition$0.79-5.6%$9.02$8.33▼$15.10$4.06M0.0146,767 shs559,937 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT+4.35%+3.81%-10.46%-25.83%-58.62%LGVNLongeveron-1.45%+14.29%-7.48%-17.07%+65.85%MRKRMarker Therapeutics+10.65%+23.84%+64.04%+58.47%-51.55%TZACTenzing Acquisition-0.59%+2.99%+2.48%-26.96%-42.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRRXDURECT1.3768 of 5 stars0.03.00.04.43.80.00.0LGVNLongeveron3.5364 of 5 stars3.65.00.00.02.01.71.3MRKRMarker Therapeutics4.2978 of 5 stars3.85.00.03.92.70.80.0TZACTenzing AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRRXDURECT 2.00HoldN/AN/ALGVNLongeveron 3.25Buy$8.67556.57% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17679.09% UpsideTZACTenzing Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TZAC, DRRX, LGVN, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025MRKRMarker TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.503/27/2025DRRXDURECTHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRRXDURECT$1.86M10.70N/AN/A$0.50 per share1.28LGVNLongeveron$2.23M8.86N/AN/A$2.68 per share0.49MRKRMarker Therapeutics$6.59M2.90N/AN/A$1.58 per share1.07TZACTenzing AcquisitionN/AN/A$0.01 per share143.10$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRRXDURECT-$27.62M-$0.15N/AN/AN/A-198.58%-300.62%-65.17%8/5/2025 (Estimated)LGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%8/13/2025 (Estimated)MRKRMarker Therapeutics-$8.24M-$1.33N/AN/AN/A-179.74%-89.63%-71.62%8/13/2025 (Estimated)TZACTenzing Acquisition$620KN/A0.00∞N/AN/A-13.32%-1.36%N/ALatest TZAC, DRRX, LGVN, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024MRKRMarker Therapeutics-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million3/26/2025Q4 2024DRRXDURECT$0.06-$0.06-$0.12$0.24$6.91 million$2.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRRXDURECTN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ATZACTenzing AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRRXDURECTN/A0.710.60LGVNLongeveronN/A7.677.67MRKRMarker TherapeuticsN/A3.153.15TZACTenzing Acquisition0.280.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRRXDURECT28.03%LGVNLongeveron10.01%MRKRMarker Therapeutics22.39%TZACTenzing Acquisition60.89%Insider OwnershipCompanyInsider OwnershipDRRXDURECT3.20%LGVNLongeveron11.20%MRKRMarker Therapeutics14.50%TZACTenzing Acquisition37.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRRXDURECT8031.04 million30.05 millionOptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableMRKRMarker Therapeutics6011.32 million9.16 millionNot OptionableTZACTenzing AcquisitionN/A5.12 millionN/ANot OptionableTZAC, DRRX, LGVN, and MRKR HeadlinesRecent News About These CompaniesFrom the Archives, 1953: Hillary and Norgay reach the top of the worldJune 8, 2023 | smh.com.auNYC Street in Queens to be Co-named After Tenzing Norgay SherpaApril 21, 2023 | patch.comTenzing Acquisition Corp. NewsOctober 15, 2022 | thestreet.comA 'Gift to the Queen': The First Ever Successful Summit of Mount EverestSeptember 22, 2022 | thewire.inTenzing Norgay Trainor Biography & MoviesSeptember 14, 2022 | tribute.caReviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH)August 12, 2021 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTZAC, DRRX, LGVN, and MRKR Company DescriptionsDURECT NASDAQ:DRRX$0.64 +0.04 (+6.67%) As of 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Longeveron NASDAQ:LGVN$1.32 -0.04 (-2.94%) As of 04:00 PM EasternLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Marker Therapeutics NASDAQ:MRKR$1.69 -0.18 (-9.63%) As of 04:00 PM EasternMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Tenzing Acquisition NASDAQ:TZACTenzing Acquisition Corp. does not have significant operations. It intends to acquire, engage in a share exchange, share reconstruction and amalgamation with, purchase all or substantially all of the assets of, enter into contractual arrangements with, or engage in any other similar business combination with one or more businesses or entities primarily operates in India. The company was founded in 2018 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
